Health and Human Services (HHS.gov) have made special provisions and guidance for Telehealth during the current public health emergency for COVID-19. Many insurers are also making accommodations for telehealth as well. Examiners can administer the IVA-2, IVA-QS, IVA-AE2 or MeSA tests remotely. BrainTrain also has Online ADHD Rating Scales which can be sent home and completed by the parent(s), grandparents, guardian, and/or Teachers and the results are uploaded back to the clinician’s computer for analysis. Remote test administration can be validly completed using the Chrome web browser or an iPad for the IVA tests and the MeSA tests requires the iPad. All remote testing requires that the testing be supervised using a separate audio-visual system such as Zoom, Web-Ex, doxy.me, Skype business, or other similar services that are HIPAA compliant. Instructions and guidelines for remote testing are provided below. A test add-on called a Remote Testing License (RTL) is necessary in order to be able administer a remote test using the Chrome Browser on a PC or an Apple iOS device, such as an iPad.
Test usages can be used either on the RTD purchased (one web browser or one iPad per applicable license) or on the PC if you have a standard license. Only one test can be run at a time on a Remote license. For a Deluxe or Premium license (Unlimited Testing administration), you will be limited to assigning no more than 5 remote test codes at a time. If you generated 5 test codes and have not completed any of these tests, then you will have to complete at least one of those remote (or cancel that test code) in order to be able to generate more new test codes.
The Web Browser and iPad RTLs can be purchased by contacting BrainTrain Sales using the email: firstname.lastname@example.org
Note that remote testing should only be administered under the clinical supervision of a qualified health care professional or technician. Remote test administration requires that the Examiner be able to validate that individuals completed the test in accordance with the specified test guidelines and performed to the best of their abilities. Testing can be administered either in-person or via interactive audio/video communication. The audio/video communication setup and functioning must enable the Examiner to view the individual being tested and their ongoing test responses during the entire test. For either in-person or remote testing it is the responsibility of the Examiner to determine if the test was administered in accordance with its guidelines and if an individual’s test compliance and effort was valid.
In general, it is the Examiner’s responsibility to determine if test results are valid or not. It is possible to use one of the Analysis options to view test responses in detail in order to review each individual test response and to check for gain any unusual patterns in test performance, including changes during the course of the test. If there are any concerns, BrainTrain will provide appropriate assistance and help.
How to use the IVA-2 Rating Scales – CLICK HERE
The IVA-2 Decision Support Software system provides the option to include up to nine FREE parent, teacher, and self ADHD rating scales that can be completed online. The rating scales are auto-scored, and summary data are confidentially downloaded to your computer. There is no identifying information ever available for any client online. To maintain confidentiality, the IVA-2 automatically generates unique random ID, passwords and identifiers for each individual. The IVA-2 is a great time-saver for you and helps you to better serve your clients’ needs. Note: You must administer a test to access the IVA ADHD rating scales. Click here to view samples of the questionnaire: Sample 1 Sample 2
DSM-5 is a trademark of the American Psychiatric Association.
The use of the IVA clinical decision software is restricted to licensed healthcare professionals with the appropriate training and experience in the administration and interpretation of this type of clinical software system. This system is not intended to be used as a standalone diagnostic instrument and by itself does not identify the presence or absence of any clinical diagnosis. The function of this decision support software is to aid providers in their analysis and interpretation of clinical data in as part of a comprehensive diagnostic evaluation. The system requires healthcare providers’ clinical input, validation and decision making in order to effectively use its suggestions and guidance in the creation of clinical reports for their clients.
The IVA-2 is a test of attention like all CPTs. The fact that the IVA-2 was found to significantly correlate with both QEEG and fMRI measures of attention provides validation that it truly measures what it was designed to measure (i.e., attentional functioning). Both QEEG and fMRI measures of attention have been found in various research studies to be useful in identifying individuals with ADHD and differentiating them with clinical efficacy.In light of the value of QEEG, the FDA approved a new QEEG based test last year after determining that it had sufficient clinical accuracy to be medically appropriate for use in helping clinicians in their diagnostic process when evaluating ADHD symptoms. This test was based in part of the research completed over 15 years ago by Dr. Joel Lubar and Dr. Vince Monastra, who identified the clinical sensitivity of QEEG analysis in classifying individuals with ADHD.
Thus, the IVA-2 test’s validity as a useful tool in the diagnostic process of clinicians is partly based on the fact that it is an accurate measure of the underlying psychophysiological processes of attention confirmed by independently completed research studies.
Why do Clinicians Need to Include the IVA-2 in ADHD Evaluations?
Research by Harrison, et al. (2007) concluded that the performance of college students who were instructed to simulate ADHD symptoms on standard ADHD rating scales was indistinguishable from those diagnosed as truly having ADHD; demonstrating that the symptoms of ADHD can be easily fabricated. Thus, clinicians cannot assume that students seeking either access to medications or academic accommodations will put forth their best effort and not exaggerate or magnify their symptom complaints. Identifying this type of “faking bad” behavior can be very challenging. However by including the IVA-2 in their comprehensive ADHD evaluations, clinicians can more accurately identify students who fake ADHD symptomatology. The IVA-2 provides clinicians with the option to evaluate possible malingering based on a published research study that demonstrated the effectiveness of the iVA-2 in identifying over 90% of college students who tried to simulate impaired test performance.